Patents by Inventor Damon Hamel
Damon Hamel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141055Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: June 29, 2023Publication date: May 2, 2024Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20230340155Abstract: Antibodies that specifically bind PD-1 or antigen binding fragments thereof, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of an inflammatory or immune disorder.Type: ApplicationFiled: June 8, 2023Publication date: October 26, 2023Inventors: Qiang Chen, Suzanne Cole, Karen Duffy, Yanxia Guo, Debra Gardner, Damon Hamel, Shannon Hitchcock, Ann Lacombe, Jinquan Luo, Ravi Malaviya, Yevgeniya Orlovsky, Pejman Soroosh, Melissa Swiecki, Deepti Wilkinson
-
Patent number: 11746161Abstract: Antibodies that specifically bind PD-1 or antigen binding fragments thereof, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of an inflammatory or immune disorder.Type: GrantFiled: December 17, 2020Date of Patent: September 5, 2023Assignee: Janssen Biotech, Inc.Inventors: Qiang Chen, Suzanne Cole, Karen Duffy, Yanxia Guo, Debra Gardner, Damon Hamel, Shannon Hitchcock, Ann Lacombe, Jinquan Luo, Ravi Malaviya, Yevgeniya Orlovsky, Pejman Soroosh, Melissa Swiecki, Deepti Wilkinson
-
Patent number: 11732050Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: May 19, 2020Date of Patent: August 22, 2023Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 10995149Abstract: Antibodies that specifically bind PD-1 or antigen binding fragments thereof, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of an inflammatory or immune disorder.Type: GrantFiled: June 4, 2018Date of Patent: May 4, 2021Assignee: Janssen Biotech, Inc.Inventors: Qiang Chen, Suzanne Cole, Karen Duffy, Yanxia Guo, Debra Gardner, Damon Hamel, Shannon Hitchcock, Ann Lacombe, Jinquan Luo, Ravi Malaviya, Yevgeniya Orlovsky, Pejman Soroosh, Melissa Swiecki, Deepti Wilkinson
-
Publication number: 20210102000Abstract: Antibodies that specifically bind PD-1 or antigen binding fragments thereof, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of an inflammatory or immune disorder.Type: ApplicationFiled: December 17, 2020Publication date: April 8, 2021Inventors: Qiang Chen, Suzanne Cole, Karen Duffy, Yanxia Guo, Debra Gardner, Damon Hamel, Shannon Hitchcock, Ann Lacombe, Jinquan Luo, Ravi Malaviya, Yevgeniya Orlovsky, Pejman Soroosh, Melissa Swiecki, Deepti Wilkinson
-
Publication number: 20200277393Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: May 19, 2020Publication date: September 3, 2020Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 10689453Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: April 12, 2019Date of Patent: June 23, 2020Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20190248910Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: April 12, 2019Publication date: August 15, 2019Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 10301392Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: May 16, 2017Date of Patent: May 28, 2019Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20180355061Abstract: Antibodies that specifically bind PD-1 or antigen binding fragments thereof, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of an inflammatory or immune disorder.Type: ApplicationFiled: June 4, 2018Publication date: December 13, 2018Inventors: Qiang Chen, Suzanne Cole, Karen Duffy, Yanxia Guo, Debra Gardner, Damon Hamel, Shannon Hitchcock, Ann Lacombe, Jinquan Luo, Ravi Malaviya, Yavegniya Orlovsky, Pejman Soroosh, Melissa Swiecki, Deepti Wilkinson
-
Publication number: 20170320957Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: May 16, 2017Publication date: November 9, 2017Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 9683046Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: July 2, 2015Date of Patent: June 20, 2017Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20150299330Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: July 2, 2015Publication date: October 22, 2015Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Patent number: 9102737Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: GrantFiled: March 15, 2013Date of Patent: August 11, 2015Assignee: Janssen Biotech, Inc.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20150087812Abstract: Antibodies and compositions capable of binding and, in a particular aspect, inhibiting the lysophosphatidylipase D activity of human autotaxin protein. The antibodies or are useful in detecting human autotaxin protein and treating diseases and disorders associated with unwanted lysophosphatidylipase D and the presence of lysophosphatidic acid, such as cancer and pulmonary diseases.Type: ApplicationFiled: March 11, 2013Publication date: March 26, 2015Applicant: JANSSEN BIOTECH, INC.Inventors: Ellen Chi, Thai Dinh, Suzanne Edavettal, Sandra Fenton, Damon Hamel, Sheri Moores, Jose Pardinas, H. Mimi Zhou, Barry L. Ziober
-
Publication number: 20130243795Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: JANSSEN BIOTECH, INC.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro